PARP Inhibitors: Science and Current Clinical Development

Por Liu, Joyce F., Silver, Daniel P.
Publicado em 2010

Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas

Por Karst, Alison M., Levanon, Keren, Duraisamy, Sekhar, Liu, Joyce F., Hirsch, Michelle S., Hecht, Jonathan L., Drapkin, Ronny
Publicado em 2011

Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model

Por Chang, De-Kuan, Peterson, Eric, Sun, Jiusong, Goudie, Calum, Drapkin, Ronny I., Liu, Joyce F., Matulonis, Ursula, Zhu, Quan, Marasco, Wayne A.
Publicado no Oncoimmunology (2015)

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube derived high-grade serous ovarian cancers

Por Karst, Alison M., Jones, Paul M., Vena, Natalie, Ligon, Azra H., Liu, Joyce F., Hirsch, Michelle S., Etemadmoghadam, Dariush, Bowtell, David D. L., Drapkin, Ronny
Publicado no Cancer Res (2013)

A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cance...

Por Liu, Joyce F., Tolaney, Sara M., Birrer, Michael, Fleming, Gini F., Buss, Mary K., Dahlberg, Suzanne E., Lee, Hang, Whalen, Christin, Tyburski, Karin, Winer, Eric, Ivy, Percy, Matulonis, Ursula A.
Publicado em 2013

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous...

Por Strickland, Kyle C., Howitt, Brooke E., Shukla, Sachet A., Rodig, Scott, Ritterhouse, Lauren L., Liu, Joyce F., Garber, Judy E., Chowdhury, Dipanjan, Wu, Catherine J., D'Andrea, Alan D., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.
Publicado no Oncotarget (2016)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olapari...

Por Lee, Jung-Min, Trepel, Jane B., Choyke, Peter, Cao, Liang, Sissung, Tristan, Houston, Nicole, Yu, Minshu, Figg, William D., Turkbey, Ismail Baris, Steinberg, Seth M., Lee, Min-Jung, Ivy, S. Percy, Liu, Joyce F., Matulonis, Ursula A., Kohn, Elise C.
Publicado no Front Oncol (2015)

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma

Por Baratta, Maria Giuseppina, Schinzel, Anna C., Zwang, Yaara, Bandopadhayay, Pratiti, Bowman-Colin, Christian, Kutt, Jennifer, Curtis, Jennifer, Piao, Huiying, Wong, Laura C., Kung, Andrew L., Beroukhim, Rameen, Bradner, James E., Drapkin, Ronny, Hahn, William C., Liu, Joyce F., Livingston, David M.
Publicado no Proc Natl Acad Sci U S A (2015)

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis

Por Levanon, Keren, Sapoznik, Stav, Bahar-Shany, Keren, Brand, Hadar, Shapira-Frommer, Ronnie, Korach, Jacob, Hirsch, Michelle S., Roh, Michael H., Miron, Alexander, Liu, Joyce F., Vena, Natalie, Ligon, Azra H., Fotheringham, Susan, Bailey, Dyane, Flavin, Richard J., Birrer, Michael J., Drapkin, Ronny I.
Publicado em 2013

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

Por Sheng, Qing, Liu, Xinggang, Fleming, Eleanor, Yuan, Karen, Piao, Huiying, Chen, Jinyun, Moustafa, Zeinab, Thomas, Roman K., Greulich, Heidi, Schinzel, Anna, Zaghlul, Sara, Batt, David, Ettenberg, Seth, Meyerson, Matthew, Schoeberl, Birgit, Kung, Andrew L., Hahn, William C., Drapkin, Ronny, Livingston, David M., Liu, Joyce F.
Publicado em 2010

In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene

Por Dunn, Gavin P., Cheung, Hiu Wing, Agarwalla, Pankaj K., Thomas, Sapana, Zektser, Yulia, Karst, Alison M., Boehm, Jesse S., Weir, Barbara A., Berlin, Aaron M., Zou, Lihua, Getz, Gad, Liu, Joyce F., Hirsch, Michelle, Vazquez, Francisca, Root, David E., Beroukhim, Rameen, Drapkin, Ronny, Hahn, William C.
Publicado em 2014

Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer target ID4

Por Ren, Yin, Cheung, Hiu Wing, von Maltzhan, Geoffrey, Agrawal, Amit, Cowley, Glenn S., Weir, Barbara A., Boehm, Jesse S., Tamayo, Pablo, Karst, Alison M., Liu, Joyce F., Hirsch, Michelle S., Mesirov, Jill P., Drapkin, Ronny, Root, David E., Lo, Justin, Fogal, Valentina, Ruoslahti, Erkki, Hahn, William C., Bhatia, Sangeeta N.
Publicado em 2012

A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer

Por Liu, Joyce F., Barry, William T., Birrer, Michael, Lee, Jung-Min, Buckanovich, Ronald J., Fleming, Gini F., Rimel, BJ, Buss, Mary K., Nattam, Sreenivasa, Hurteau, Jean, Luo, Weixiu, Quy, Philippa, Whalen, Christin, Obermayer, Lisa, Lee, Hang, Winer, Eric P., Kohn, Elise C., Ivy, S. Percy, Matulonis, Ursula A.
Publicado no Lancet Oncol (2014)

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

Por Johnson, Neil, Johnson, Shawn F., Yao, Wei, Li, Yu-Chen, Choi, Young-Eun, Bernhardy, Andrea J., Wang, Yifan, Capelletti, Marzia, Sarosiek, Kristopher A., Moreau, Lisa A., Chowdhury, Dipanjan, Wickramanayake, Anneka, Harrell, Maria I., Liu, Joyce F., D’Andrea, Alan D., Miron, Alexander, Swisher, Elizabeth M., Shapiro, Geoffrey I.
Publicado em 2013

Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics

Por Liu, Joyce F., Palakurthi, Sangeetha, Zeng, Qing, Zhou, Shan, Ivanova, Elena, Huang, Wei, Zervantonakis, Ioannis K., Selfors, Laura M., Shen, Yiping, Pritchard, Colin C., Zheng, Mei, Adleff, Vilmos, Papp, Eniko, Piao, Huiying, Novak, Marian, Fotheringham, Susan, Wulf, Gerburg M., English, Jessie, Kirschmeier, Paul, Velculescu, Victor, Paweletz, Cloud, Mills, Gordon B., Livingston, David, Brugge, Joan S., Matulonis, Ursula, Drapkin, Ronny
Publicado no Clin Cancer Res (2016)